A process for resolving racemic (±)-10,l l-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5- carboxamide comprising reacting (±)-10,l l-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5- carboxamide with S-ibuprofen or a pharmaceutically acceptable salt thereof to form a mixture of the SS and SR diastereomer esters of 10,l l-dihydro-10-hydroxy-5H-dibenz[b,f]azepine-5- carboxamide, followed by separating the SS-ibuprofen ester from the SR ibuprofen ester, and removal of the S-ibuprofen moiety to form S-(+)-10,l l-dihydro-10-hydroxy-5H- dibenz[b,f]azepine-5-carboxamide with a chiral purity greater than 90%.
将(±)-10,11-二氢-10-羟基-5H-二苯并[b,f]氮杂-5-羧酰胺与S-
布洛芬或其药用可接受的盐反应,形成10,11-二氢-10-羟基-5H-二苯并[b,f]氮杂-5-羧酰胺的SS和SR对映异构体酯的混合物,然后将SS-
布洛芬酯与SR-
布洛芬酯分离,并去除S-
布洛芬基团,形成手性纯度大于90%的S-(+)-10,11-二氢-10-羟基-5H-二苯并[b,f]氮杂-5-羧酰胺。